‒ Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒
‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒
‒ Company has.
California settles with drugmaker it's working with on overdose meds sfchronicle.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sfchronicle.com Daily Mail and Mail on Sunday newspapers.
FDA approves generic over-the-counter naloxone nasal spray healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.